Geneyx Company
"Integrated End-to-end Solution for Genomic Data."
Geneyx develops an integrated and secure genetic data bank. The company's cloud-based system is designed for pharmaceutical research, universities, and translational research, enabling the development of innovative drugs and novel therapeutic and diagnostic tools.
Geneyx addresses the total needs of genetic testing labs worldwide: quality control, a customized pipeline, unlimited secured storage, analysis and interpretation, ready-to-run extra tests, comprehensive reports, and better monetization of the data by charging pharmaceutical companies access fees and sharing the revenue with the labs. It ensures transparent and traceable data transactions by creating a unified data bank that enhances genetic data diversification.
Geneyx's data bank is GDPR and HIPAA compliant.
The company is currently working alongside a public–private consortium in Israel to collect samples and sequence genomes from thousands of COVID-19 patients in an effort to identify protective and risk-bearing genetic factors with the hopes of discovering new diagnostic and treatment methods. Alongside Geneyx, the consortium partners include the Israel Ministry of Health, the Israel Innovation Authority, Sourasky (Ichilov) Medical Center, and Rambam Health Care Campus.
Combating Coronavirus Pandemic:
Geneyx's solution helps address the Coronavirus Pandemic.
Geneyx develops an integrated and secure genetic data bank. The company's cloud-based system is designed for pharmaceutical research, universities, and translational research, enabling the development of innovative drugs and novel therapeutic and diagnostic tools.
Geneyx addresses the total needs of genetic testing labs worldwide: quality control, a customized pipeline, unlimited secured storage, analysis and interpretation, ready-to-run extra tests, comprehensive reports, and better monetization of the data by charging pharmaceutical companies access fees and sharing the revenue with the labs. It ensures transparent and traceable data transactions by creating a unified data bank that enhances genetic data diversification.
Geneyx's data bank is GDPR and HIPAA compliant.
The company is currently working alongside a public–private consortium in Israel to collect samples and sequence genomes from thousands of COVID-19 patients in an effort to identify protective and risk-bearing genetic factors with the hopes of discovering new diagnostic and treatment methods. Alongside Geneyx, the consortium partners include the Israel Ministry of Health, the Israel Innovation Authority, Sourasky (Ichilov) Medical Center, and Rambam Health Care Campus.
Combating Coronavirus Pandemic:
Geneyx's solution helps address the Coronavirus Pandemic.
Technology:
COVID Treatments
Industry:
Treatment Development
Headquarters:
Israel
Founded Date:
2018
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership